The Solute Carrier (SLC) Transporter Superfamily as Therapeutic Targets for the Treatment of Ovarian Serous Cystadenocarcinoma

Abstract

Ovarian serous cystadenocarcinoma (OV) is one of the deadliest gynecologic cancers, primarily due to late-stage diagnosis and limited treatment options. Precision oncology seeks to personalize cancer treatment based on individual genetic profiles and tumor characteristics. The solute carrier (SLC) transporter superfamily, consisting of over 400 proteins across 65 families, is vital for numerous cellular functions and presents promising therapeutic targets. This study provides a comprehensive analysis of SLC transporters by integrating mRNA and protein expression from The Cancer Genome Atlas (TCGA) and The Human Protein Atlas (HPA). Gene Set Enrichment Analysis (GSEA) was performed to evaluate the involvement of SLC transporters in diverse oncogenic pathways. Significant upregulation of SLC transporters was observed in tumor tissues compared to normal tissues, notably for SLC57A5, SLC16A3, SLC20A2, and SLC34A2. This upregulation was associated with poorer overall survival (OS) and disease-specific survival (DSS). Gene Set Enrichment Analysis (GSEA) indicated that these transporters are significantly involved in crucial oncogenic pathways, including the epithelial-mesenchymal transition (EMT), angiogenesis, and Hedgehog signaling pathways. This study identifies SLC transporters as potential biomarkers and therapeutic targets in OV. By targeting these transporters with small molecule inhibitors, it may be possible to disrupt essential metabolic pathways in cancer cells, thereby enhancing treatment efficacy and improving patient outcomes. This research establishes a foundation for the development of SLC-targeted therapies in precision oncology, aiming to improve survival rates for patients with OV.

Keywords

• SLC superfamily transporters

• Precision oncology

• Ovarian cancer

• Therapeutic targets